| Pharmacokinetic–pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score VP Reddy, M Kozielska, AA Suleiman, M Johnson, A Vermeulen, J Liu, ... Schizophrenia research 146 (1), 153-161, 2013 | 48* | 2013 |
| Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility VP Reddy, M Kozielska, AA Suleiman, M Johnson, A Vermeulen, J Liu, ... Schizophrenia research 146 (1-3), 144-152, 2013 | 48* | 2013 |
| A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole S Frechen, L Junge, TI Saari, AA Suleiman, D Rokitta, PJ Neuvonen, ... Clinical pharmacokinetics 52, 763-781, 2013 | 39 | 2013 |
| Association of biomarker cutoffs and endoscopic outcomes in Crohn’s disease: a post hoc analysis from the CALM study W Reinisch, R Panaccione, P Bossuyt, F Baert, A Armuzzi, X Hébuterne, ... Inflammatory Bowel Diseases 26 (10), 1562-1571, 2020 | 33 | 2020 |
| Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials VP Reddy, M Kozielska, M Johnson, AA Suleiman, A Vermeulen, J Liu, ... Clinical pharmacokinetics 51, 261-275, 2012 | 33 | 2012 |
| Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment AHM de Vries Schultink, AA Suleiman, JHM Schellens, JH Beijnen, ... European journal of clinical pharmacology 72, 645-653, 2016 | 31 | 2016 |
| Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis A Khatri, D Eckert, R Oberoi, A Suleiman, Y Pang, L Cheng, AA Othman The Journal of Clinical Pharmacology 59 (12), 1656-1668, 2019 | 29 | 2019 |
| Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn’s disease: analyses of phase I and II trials AA Suleiman, A Khatri, M Minocha, AA Othman Clinical pharmacokinetics 58, 375-387, 2019 | 28 | 2019 |
| Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam D Tomalik‐Scharte, AA Suleiman, S Frechen, D Kraus, U Kerkweg, ... The Journal of Clinical Pharmacology 54 (10), 1162-1169, 2014 | 27 | 2014 |
| Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I–III clinical trials AA Suleiman, M Minocha, A Khatri, Y Pang, AA Othman Clinical Pharmacokinetics 58, 1309-1321, 2019 | 26 | 2019 |
| Clinical pharmacokinetics and pharmacodynamics of risankizumab in psoriasis patients Y Pang, A Khatri, AA Suleiman, AA Othman Clinical Pharmacokinetics 59, 311-326, 2020 | 25 | 2020 |
| Pharmacokinetic–Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects With Markov Elements VP Reddy, KJ Petersson, AA Suleiman, A Vermeulen, JH Proost, ... CPT: Pharmacometrics and Systems Pharmacology 1 (e1), 2012 | 25 | 2012 |
| Modeling tumor dynamics and overall survival in advanced non–small-cell lung cancer treated with erlotinib AA Suleiman, S Frechen, M Scheffler, T Zander, D Kahraman, C Kobe, ... Journal of Thoracic Oncology 10 (1), 84-92, 2015 | 18 | 2015 |
| Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program GR Galluppi, S Brar, L Caro, Y Chen, N Frey, HP Grimm, DJ Rudd, CC Li, ... Clinical Pharmacology and Therapeutics 110 (5), 1172, 2021 | 17 | 2021 |
| Exposure–Response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis AA Suleiman, A Khatri, RK Oberoi, AA Othman Clinical Pharmacokinetics 59, 575-589, 2020 | 17 | 2020 |
| Modeling NSCLC progression: recent advances and opportunities available AA Suleiman, L Nogova, U Fuhr The AAPS journal 15, 542-550, 2013 | 17 | 2013 |
| Expanding the repertoire for “large small molecules”: prodrug ABBV-167 efficiently converts to venetoclax with reduced food effect in healthy volunteers AH Salem, ZF Tao, OF Bueno, J Chen, S Chen, R Edalji, SW Elmore, ... Molecular Cancer Therapeutics 20 (6), 999-1008, 2021 | 13 | 2021 |
| Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: a phase I trial with early pharmacodynamic FDG‐PET assessment L Nogova, C Mattonet, M Scheffler, M Taubert, M Gardizi, ML Sos, ... Cancer Medicine 9 (14), 4991-5007, 2020 | 13 | 2020 |
| Exposure–response relationships for efficacy and safety of risankizumab in phase II and III trials in psoriasis patients A Khatri, AA Suleiman, AR Polepally, AA Othman Clinical Pharmacology & Therapeutics 107 (2), 378-387, 2020 | 13 | 2020 |
| Exposure‐safety analyses identify predictors of change in bone mineral density and support elagolix labeling for endometriosis‐associated pain A Abbas Suleiman, A Nader, I Winzenborg, D Beck, AR Polepally, J Ng, ... CPT: Pharmacometrics & Systems Pharmacology 9 (11), 639-648, 2020 | 11 | 2020 |
